Kimberly Lynn Blackwell

Adjunct Professor in the Department of Medicine

Medicine, Medical Oncology

black034@mc.duke.edu

Duke Box 3893, Durham, NC 27710

Room 3818 Duke South, Durham, NC

More About This Person

At a Glance

Credentials
1. Education
2. Training & Certifications

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise
1. Global Scholarship

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition
1. In the News

Professional Activities

Selected Grants

Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer

ResearchCo Investigator · Awarded by Department of Defense · 2016 - 2024

Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy

ResearchCo Investigator · Awarded by Department of Defense · 2012 - 2022

Single cell functional dissection of tumor microenviornment-driven drug resistance

ResearchCollaborator · Awarded by National Institutes of Health · 2018 - 2020

Targeting differential apoptosis regulation in triple negative breast cancer

ResearchCollaborator · Awarded by Department of Defense · 2016 - 2019

A Phase Ib, Open-Label, Two-Arm Study Evaluating The Safety And Pharmacokinetics Of Atezolizumab (ANTI-PD-L1 Antibody) In Combination With Trastuzumab Emtansine Or With Trastuzumab And Pertuzumab In Subjects With HER2 Positive Breast Cancer

Clinical TrialPrincipal Investigator · Awarded by F. Hoffmann-La Roche Ltd · 2016 - 2018

Examining the Role of Cholesterol Metabolites on the Estrogen Receptor Signaling Pathway

ResearchPrincipal Investigator · Awarded by Susan G. Komen Breast Cancer Foundation · 2015 - 2018

Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients with New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2016 - 2018

Enhancing Efficacy of Chemotherapy in Triple Negatiave/Basal-like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

Clinical TrialPrincipal Investigator · Awarded by University of California - San Francisco · 2013 - 2018

A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

Clinical TrialPrincipal Investigator · Awarded by Merrimack Pharmaceuticals · 2016 - 2018

Directed Chemotherapy Delivery for Leptomeningeal Metastases

ResearchCo Investigator · Awarded by Minnetronix, Inc · 2016 - 2017

EISAI BREAST CANCER ADVANCED TRAINING

ConferencePrincipal Investigator · Awarded by Eisai, Inc. · 2016 - 2016

Clinical Oncology Research Career Development Program

ResearchMentor · Awarded by National Institutes of Health · 2009 - 2015

Novartis Breast Cancer Practicum

ConferencePrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2014 - 2014

Understanding Patient Expectations of Treatment Outcomes

ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2011

Role of XIAP in Therapeutic Resistance in Inflammatory Breast Cancer

FellowshipConsultant · Awarded by Dept. of the Army -- USAMRAA · 2008 - 2010

Antiestrogenic Effects on Tumor Angiogenesis

FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2006